Whitehawk Therapeutics (WHWK) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.7 million.
- Whitehawk Therapeutics' Income towards Parent Company fell 4106.02% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 6725.19%. This contributed to the annual value of -$63.7 million for FY2024, which is 315.37% up from last year.
- According to the latest figures from Q3 2025, Whitehawk Therapeutics' Income towards Parent Company is -$17.7 million, which was down 4106.02% from -$52.8 million recorded in Q2 2025.
- In the past 5 years, Whitehawk Therapeutics' Income towards Parent Company registered a high of -$1.5 million during Q2 2021, and its lowest value of -$87.1 million during Q3 2021.
- Its 5-year average for Income towards Parent Company is -$20.3 million, with a median of -$16.0 million in 2021.
- As far as peak fluctuations go, Whitehawk Therapeutics' Income towards Parent Company crashed by 291134.16% in 2021, and later surged by 8338.0% in 2022.
- Over the past 5 years, Whitehawk Therapeutics' Income towards Parent Company (Quarter) stood at -$16.0 million in 2021, then increased by 12.99% to -$13.9 million in 2022, then decreased by 16.93% to -$16.3 million in 2023, then decreased by 12.32% to -$18.3 million in 2024, then increased by 3.16% to -$17.7 million in 2025.
- Its Income towards Parent Company was -$17.7 million in Q3 2025, compared to -$52.8 million in Q2 2025 and -$14.4 million in Q1 2025.